PRLD
Prelude Therapeutics Incorporated
NASDAQ · Healthcare · Biotechnology · US
$5.46
+4.00%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 7.86x
- P/S forward
- 9.11x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.26x
- Price / sales
- 19.43x
- Price / cash flow
- -13.10x
Enterprise value
- Enterprise value
- $301.6M
- EV / sales
- 13.45x
- EV / EBITDA
- -5.12x
- EV / EBIT
- -4.48x
- Market cap
- $435.7M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026